InvestorLens

CADL — CANDEL THERAPEUTICS INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying CADL?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
67
Institutional Conviction
Net distribution · 2 buying vs 1 selling last quarter
43
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their CADL position last quarter, 2 bought and 1 sold (67% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Izzy Englander, Steve Cohen)
  • +3 tracked investors reported holding CADL at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About CANDEL THERAPEUTICS INC (CADL)

CANDEL THERAPEUTICS INC (CADL) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $11M. Across recent filings, tracked investors recorded 4 new positions, 4 increased, 1 reduced, and 4 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in CADL

62
/100
Institutional Accumulation
Added / Increased8
Reduced1
Exited4
BearishBullish
Crowded Trade Score™

How many top investors track CADL

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

CADL Ownership Composition

How CANDEL THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
3
tracked investors
Total Reported
$15.2M
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(3)
100.0%

Tracked investors currently reporting CADL

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    1.1M
    Value
    $11.3M
    % Portfolio
    0.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    251.9K
    Value
    $2.6M
    % Portfolio
    0.00%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    129.2K
    Value
    $1.3M
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold CADL?
3 tracked institutional investors disclosed a position in CADL (CANDEL THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of CADL?
Izzy Englander, Millennium Management, holds the largest disclosed position in CADL, valued at $11M.
Did institutional ownership of CADL increase or decrease?
Across recent 13F filings, tracked investors recorded 4 new positions, 4 increased, 1 reduced, and 4 fully exited CADL.
Where does this CADL ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.